Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Wells Fargo Downgrades Prometheus Biosciences to Equal-Weight, Raises Price Target to $200

Author: Benzinga Newsdesk | April 18, 2023 05:47am
Wells Fargo analyst Chris Carey downgrades Prometheus Biosciences (NASDAQ:RXDX) from Overweight to Equal-Weight and raises the price target from $164 to $200.

Posted In: RXDX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist